ArticleBrain and behavior2025
The ABILHAND-23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Analysis With the Nine Hole Peg Test.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Task-oriented virtual reality and brain functional plasticity in progressive multiple sclerosis: A randomized controlled trial on upper limb rehabilitation.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Trial
- From Phenotypes to Spectrum: Rethinking RRMS, SPMS and PPMS in the Era of PIRA-A Framework Integrating PIRA, Smouldering-Associated Worsening, and Neurologic Reserve to Facilitate Earlier Recognition of Progression.Neurology international · 2026Review
- The ABILHAND-23 Patient Reported Outcome Measure in Secondary Progressive Multiple Sclerosis: A Cross-Sectional Analysis With the Nine Hole Peg Test.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundPeople with progressive multiple sclerosis (pwPMS), who typically have established lower limb dysfunction, experience greater disability from upper limb dysfunction (ULD). The 9-hole peg test (9HPT) is the primary clinical measure for ULD but does not fully capture the patient experience. The ABILHAND-23 is a well-validated patient-reported outcome measure (PROM) that evaluates bimanual ability in daily function. However, no large-scale studies have assessed if the 9HPT reflects the individual ULD experience in pwPMS.
objectivesWe sought to (van Munster et al. 2023) assess the associations between the ABILHAND-23 and 9HPT, and (Huertas-Hoyas et al. 2020) to assess the ability of the 9HPT and other relevant covariables to predict ABILHAND-23 scores, using baseline data from the MS-STAT2 trial, a phase 3 study on simvastatin for secondary progressive MS (SPMS).
methodsA cross-sectional analysis of baseline data from the UCLH cohort of the MS-STAT2 trial was performed using multiple linear regression to predict ABILHAND-23 logit scores by 9HPT.
results225 participants were analyzed. ABILHAND-23 scores moderately correlated with the 9HPT (rho = 0.47). Regression analysis showed that better 9HPT performance modestly predicted ABILHAND-23 logits (β = -0.05, SE 0.008, p-value < 0.001).
conclusionThe 9HPT only modestly predicts the ABILHAND-23 but does not fully capture the individual's daily disability experience, underscoring the value of patient-reported outcome measures (PROMs) like the ABILHAND-23 in clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.